Mutant hypoxia inducible factor-1 HIF-1

摘要

Substantially purified stable human hypoxia-inducible factor-1 alpha (sHIF-1 alpha ) mutein is provided. Polynucleotides encoding stable human hypoxia-inducible factor-1 alpha mutein are also provided. A method is provided for treating a hypoxia-related tissue damage in a subject by administering to the subject a therapeutically effective amount of a sHIF-1 alpha mutein or a nucleotide sequence including an expression control sequence operatively linked to a polynucleotide encoding a stable hypoxia-inducible factor-1 alpha mutein. Formulations are provided for the administration of stable human hypoxia inducible factor-1 alpha (HIF-1 alpha ) polypeptide or a polynucleotide encoding stable human hypoxia inducible factor-1 alpha (HIF-1 alpha ) to a patient having hypoxia-related tissue damage.